宫颈癌图像引导自适应近距离放疗后膀胱瘘、出血和膀胱炎的危险因素与剂量效应:EMBRACE分析
基于EMBRACE-I前瞻性多中心研究,分析1416例局部晚期宫颈癌接受放化疗及图像引导自适应近距离放疗(IGABT)患者的膀胱毒性。在无膀胱浸润患者中,膀胱D2cm3与≥2级瘘、出血和膀胱炎相关,D2cm3从75 Gy增至80 Gy时4年≥2级膀胱炎发生率从8%升至13%,强调个体化IGABT计划持续优化的必要性。
要点
- 基线泌尿系统症状和超重/肥胖是多数膀胱毒性终点的显著危险因素。
- 膀胱D2cm3与≥2级瘘、出血和膀胱炎相关,ICRU膀胱点剂量与EORTC明显疼痛相关。
- 膀胱D2cm3从75 Gy增至80 Gy,4年≥2级膀胱炎发生率从8%升至13%。
核心结论
- 在无膀胱浸润的局部晚期宫颈癌IGABT患者中,识别出膀胱瘘、出血和膀胱炎的临床及治疗相关危险因素。
- 膀胱D2cm3存在剂量效应,支持个体化IGABT计划中持续优化的必要性。
研究设计与样本
- EMBRACE-I前瞻性多中心研究,纳入1416例局部晚期宫颈癌患者,其中1153例和884例无膀胱浸润者分别可评估CTCAE和EORTC条目。
- 中位随访48(范围3-120)个月,采用Cox回归分析危险因素。
主要发现
- ≥2级瘘、出血和膀胱炎的粗发生率分别为0.7%、2.7%和8.8%。
- EORTC「相当多」或更差的疼痛和排尿困难发生率分别为16%和14%。
- 基线泌尿系统症状和超重/肥胖是大多数终点的显著危险因素。
- 膀胱D2cm3与≥2级瘘、出血和膀胱炎相关,ICRU膀胱点剂量与EORTC疼痛「相当多」或更差相关。
关键数值与推荐
- 膀胱D2cm3从75 Gy增至80 Gy,4年≥2级膀胱炎 actuarial 估计从8%升至13%。
临床怎么用
- 在IGABT计划中应关注膀胱D2cm3,并考虑基线泌尿系统症状及超重/肥胖等危险因素进行个体化优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify patient- and treatment-related risk factors for fistula, bleeding, cystitis, pain and difficulty in voiding in locally advanced cervical cancer patients treated with radio(chemo)therapy and image-guided adaptive brachytherapy (IGABT). MATERIAL AND METHODS: Morbidity within the EMBRACE-I study was prospectively reported for physician-assessed (CTCAE) fistula, bleeding and cystitis and patient-reported (EORTC) pain and difficulty in voiding. Analysis of risk factors was performed in patients without bladder infiltration. Risk factors were tested with Cox regression for grade (G) ≥ 3 cystitis, for G ≥ 2 fistula, bleeding and cystitis, and for EORTC "very much" and "quite a bit" or worse. RESULTS: Of 1416 patients enrolled, 1153 and 884 patients without bladder infiltration were evaluable for the analysis of CTCAE and EORTC items, respectively. Median follow-up was 48[3-120] months. Crude incidence rates for G ≥ 2 fistula, bleeding and cystitis were 0.7%, 2.7% and 8.8%, respectively, and 16% and 14% for "quite a bit" or worse pain and difficulty in voiding, respectively. Baseline urinary morbidity and overweight/obesity were significant risk factors for most endpoints. Bladder D2cm3 correlated with G ≥ 2 fistula, bleeding and cystitis, while ICRU bladder point dose correlated with EORTC pain "quite a bit" or worse. An increase from 75 Gy to 80 Gy in bladder D2cm3 resulted in an increase from 8% to 13% for 4-year actuarial estimate of G ≥ 2 cystitis. CONCLUSION: Clinical and treatment-related risk factors for bladder fistula, bleeding and cystitis were identified within a prospective and multi-institutional setting. A dose-effect was established with bladder D2cm3, reinforcing the importance of continued optimization during individualized IGABT planning.
引用
- Spampinato S, Fokdal LU, Pötter R, et al. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. Radiother Oncol. 2021. PMID: 33545254. doi:10.1016/j.radonc.2021.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。